Sotagliflozin - Lexicon Pharmaceuticals
Alternative Names: INPEFA; LP-802034; LX-4211; SAR 439954; ZynquistaLatest Information Update: 13 Sep 2024
At a glance
- Originator Lexicon Pharmaceuticals
- Developer Lexicon Pharmaceuticals; Sanofi
- Class Alcohols; Antihyperglycaemics; Chlorobenzenes; Glycosides; Heart failure therapies; Phenyl ethers; Pyrans; Small molecules; Sulfhydryl compounds
- Mechanism of Action Sodium-glucose transporter 1 inhibitors; Sodium-glucose transporter 2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Heart failure; Type 2 diabetes mellitus
- Registered Type 1 diabetes mellitus
- Phase III Hypertrophic cardiomyopathy
Most Recent Events
- 10 Sep 2024 Updated efficacy data from the phase III SOTA-INS trial in Type-2 diabetes mellitus released by Lexicon Pharmaceuticals
- 21 Aug 2024 Lexicon Pharmaceuticals announces intention to meet with the Endocrinologic and Metabolic Drugs Advisory Committee for sotagliflozin for Type 1 diabetes and chronic kidney disease in October 2024
- 16 Jul 2024 The US FDA sets PDUFA date of 20 December 2024 for NDA review of sotagliflozin for for type 1 diabetes and chronic kidney disease